Locke, FL; Chou, J; Vardhanabhuti, S; Perbost, R; Dreger, P; Hill, BT; Lee, C; Zinzani, PL; Kroeger, N; Lopez-Guillermo, A; Greinix, H; Zhang, WS; Tiwari, G; To, CA; Cheng, PC; Bot, A; Shen, R; Filosto, S; Galon, J.
Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
J CLIN ONCOL. 2022; 40(16):
[Oral Communication]
Web of Science